Atrium Therapeutics (RNA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Atrium Therapeutics (RNA) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.00 of bullish evidence against -0.36 bearish.

Atrium Therapeutics last closed at $8.40, +1.69% on the session.

Against the IVW growth benchmark the position is +0.89% over the forecast window.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

20 graded predictions for RNA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Atrium Therapeutics in the 13th percentile on return on equity, where 100 is best.

Atrium Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $141.30M.

StockMap tracks Atrium Therapeutics as the 268th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Atrium Therapeutics ranks 334th of 381 in the group, against a group median of -0.08.